Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B
暂无分享,去创建一个
M. Zaki | Aamal A. Al-Mutairi | V. Masand | S. Al-Hussain | Abdul Samad | M. Rathore | Siddhartha Akasapu | S. D. Thakur
[1] S. N. Bukhari,et al. Perceiving the Concealed and Unreported Pharmacophoric Features of the 5-Hydroxytryptamine Receptor Using Balanced QSAR Analysis , 2022, Pharmaceuticals.
[2] M. Zaki,et al. Mechanistic Analysis of Chemically Diverse Bromodomain-4 Inhibitors Using Balanced QSAR Analysis and Supported by X-ray Resolved Crystal Structures , 2022, Pharmaceuticals.
[3] V. M. Patil,et al. Exploring the Prominent and Concealed Inhibitory Features for Cytoplasmic Isoforms of Hsp90 Using QSAR Analysis , 2022, Pharmaceuticals.
[4] Wei-Chang Fu,et al. Discovery of a novel Aurora B inhibitor GSK650394 with potent anticancer and anti-aspergillus fumigatus dual efficacies in vitro , 2021, Journal of enzyme inhibition and medicinal chemistry.
[5] Christopher J. Woods,et al. Exploration of the structural requirements of Aurora Kinase B inhibitors by a combined QSAR, modelling and molecular simulation approach , 2021, Scientific Reports.
[6] Shi-wu Chen,et al. Aurora kinase inhibitors: a patent review (2014-2020) , 2021, Expert opinion on therapeutic patents.
[7] Z. Dong,et al. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy , 2021, Molecular cancer.
[8] Paola Gramatica,et al. Principles of QSAR Modeling , 2020 .
[9] Ana Sovic Krzic,et al. Estimation of Random Accuracy and its Use in Validation of Predictive Quality of Classification Models within Predictive Challenges , 2019, Croatica Chemica Acta.
[10] B. Rogister,et al. The functional diversity of Aurora kinases: a comprehensive review , 2018, Cell Division.
[11] Roberto Todeschini,et al. On the Misleading Use of QF32 for QSAR Model Comparison , 2018, Molecular informatics.
[12] Andreas Bender,et al. Identification of Novel Aurora Kinase A (AURKA) Inhibitors via Hierarchical Ligand-Based Virtual Screening , 2017, J. Chem. Inf. Model..
[13] H. Bhatt,et al. A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies. , 2017, European journal of medicinal chemistry.
[14] Vesna Rastija,et al. PyDescriptor : A new PyMOL plugin for calculating thousands of easily understandable molecular descriptors , 2017 .
[15] Shufeng Zhou,et al. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor , 2016, Clinical and experimental pharmacology & physiology.
[16] Inho Choi,et al. Computer Aided Drug Design: Success and Limitations. , 2016, Current pharmaceutical design.
[17] David A. Winkler,et al. Understanding the Roles of the "Two QSARs" , 2016, J. Chem. Inf. Model..
[18] S. Linardopoulos,et al. Aurora Kinase Inhibitors: Current Status and Outlook , 2015, Front. Oncol..
[19] Stephani Joy Y Macalino,et al. Role of computer-aided drug design in modern drug discovery , 2015, Archives of Pharmacal Research.
[20] P. Gramatica,et al. Tautomerism and multiple modelling enhance the efficacy of QSAR: antimalarial activity of phosphoramidate and phosphorothioamidate analogues of amiprophos methyl , 2014, Medicinal Chemistry Research.
[21] Paola Gramatica,et al. External Evaluation of QSAR Models, in Addition to Cross‐Validation: Verification of Predictive Capability on Totally New Chemicals , 2014, Molecular informatics.
[22] F. Villa,et al. Structure of Aurora B–INCENP in complex with barasertib reveals a potential transinhibitory mechanism , 2014, Acta crystallographica. Section F, Structural biology communications.
[23] A. Tropsha,et al. Data Set Modelability by QSAR , 2014, J. Chem. Inf. Model..
[24] J. Dearden,et al. QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.
[25] Paola Gramatica,et al. QSARINS: A new software for the development, analysis, and validation of QSAR MLR models , 2013, J. Comput. Chem..
[26] Paola Gramatica,et al. QSAR Modeling is not “Push a Button and Find a Correlation”: A Case Study of Toxicity of (Benzo‐)triazoles on Algae , 2012, Molecular informatics.
[27] A. Tropsha,et al. Does Rational Selection of Training and Test Sets Improve the Outcome of QSAR Modeling? , 2012, J. Chem. Inf. Model..
[28] S. Knapp,et al. Crystal Structure of Human Aurora B in Complex with INCENP and VX-680 , 2012, Journal of medicinal chemistry.
[29] Paola Gramatica,et al. Real External Predictivity of QSAR Models. Part 2. New Intercomparable Thresholds for Different Validation Criteria and the Need for Scatter Plot Inspection , 2012, J. Chem. Inf. Model..
[30] D. Zheleva,et al. Aurora kinase inhibitors: Progress towards the clinic , 2012, Investigational New Drugs.
[31] Chris Morley,et al. Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.
[32] Paola Gramatica,et al. Real External Predictivity of QSAR Models: How To Evaluate It? Comparison of Different Validation Criteria and Proposal of Using the Concordance Correlation Coefficient , 2011, J. Chem. Inf. Model..
[33] Paola Gramatica,et al. QSAR model reproducibility and applicability: A case study of rate constants of hydroxyl radical reaction models applied to polybrominated diphenyl ethers and (benzo‐)triazoles , 2011, J. Comput. Chem..
[34] P. Lan,et al. 3D-QSAR and molecular docking studies of azaindole derivatives as Aurora B kinase inhibitors , 2011, Journal of molecular modeling.
[35] CHUN WEI YAP,et al. PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..
[36] Xiaohui Fan,et al. Why QSAR fails: an empirical evaluation using conventional computational approach. , 2011, Molecular pharmaceutics.
[37] Igor V. Tetko,et al. Applicability Domains for Classification Problems: Benchmarking of Distance to Models for Ames Mutagenicity Set , 2010, J. Chem. Inf. Model..
[38] Alexander Tropsha,et al. Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..
[39] M. Saif,et al. Aurora kinase inhibitors as anti-cancer therapy , 2010, Anti-cancer drugs.
[40] S. Cho,et al. Structural studies of B-type Aurora kinase inhibitors using computational methods , 2010, Acta Pharmacologica Sinica.
[41] R. Todeschini,et al. Molecular Descriptors for Chemoinformatics: Volume I: Alphabetical Listing / Volume II: Appendices, References , 2009 .
[42] G. Bottegoni,et al. Small molecule aurora kinases inhibitors. , 2009, Current medicinal chemistry.
[43] J. Pollard,et al. Discovery and development of aurora kinase inhibitors as anticancer agents. , 2009, Journal of medicinal chemistry.
[44] Stephen S. Taylor,et al. Mitotic drivers—inhibitors of the Aurora B Kinase , 2009, Cancer and Metastasis Reviews.
[45] Edward H. Kerns,et al. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .
[46] Alexander Golbraikh,et al. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.
[47] Paola Gramatica,et al. Principles of QSAR models validation: internal and external , 2007 .
[48] Paola Gramatica,et al. The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models , 2003 .
[49] Douglas M. Hawkins,et al. Assessing Model Fit by Cross-Validation , 2003, J. Chem. Inf. Comput. Sci..
[50] James J. P. Stewart,et al. MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..
[51] Jerzy Leszczynski,et al. Applicability Domain: A Step Toward Confident Predictions and Decidability for QSAR Modeling. , 2018, Methods in molecular biology.
[52] S. S. Imam,et al. Computer Aided Drug Design: A Novel Loom To Drug Discovery , 2017 .
[53] V. Rastija,et al. Effect of information leakage and method of splitting (rational and random) on external predictive ability and behavior of different statistical parameters of QSAR model , 2014, Medicinal Chemistry Research.
[54] Paola Gramatica,et al. On the development and validation of QSAR models. , 2013, Methods in molecular biology.
[55] V. Rastija,et al. Does tautomerism influence the outcome of QSAR modeling? , 2013, Medicinal Chemistry Research.
[56] Glenn Fung,et al. On the Dangers of Cross-Validation. An Experimental Evaluation , 2008, SDM.
[57] Roberto Todeschini,et al. Handbook of Molecular Descriptors , 2002 .